Medifast Inc (MED) · Oct 26, 2026 · Earnings
Beat — Adjusted EPS $(0.19) vs roughly $(0.35) consensus
Medifast’s Q3 earnings beat adjusted EPS expectations, but revenue fell 19% as active coaches nearly halved and GLP-1 pressure persisted.
Medifast is in the execution phase of its pivot from traditional coach-led weight loss toward Trilivy, a broader metabolic-health system, while GLP-1 adoption continues to pressure client acquisition and the coach network. The company has launched the new brand, products, compensation plan, and Coach Hub, but the turnaround still depends on rebuilding coach growth.
| Metric | Q3 2026 | Q3 2025 / expectation |
|---|---|---|
| Revenue | $72.0M | $89.4M prior year; roughly $71.3M consensus |
| GAAP diluted EPS | $(1.57) | $(0.21) prior year |
| Adjusted diluted EPS | $(0.19) | Roughly $(0.35) consensus |
| Active earning coaches | 10,200 | 19,500 prior year |
| Adjusted EBITDA excluding interest | $1.9M | $1.7M prior year |
| Cash, cash equivalents and investments | $172.5M | $167.3M at Dec. 31, 2025 |
The quarter technically beat expectations, but mainly because the comparison is against a still-low bar. Revenue of $72.0 million was slightly above the published consensus of roughly $71.3 million, while adjusted loss per share of $0.19 was better than the roughly $0.35 expected. The GAAP loss was much worse because Catalyst restructuring charges added $15.4 million to the quarter; excluding those charges, the loss narrowed to $2.1 million, or $0.19 per diluted share.
The underlying customer-acquisition engine remains the central problem. Revenue fell 19.4% year over year as active earning coaches dropped 47.7% to 10,200, and management expects that count to keep declining through the end of 2026. 〔0〕 Higher revenue per remaining coach—$7,064 versus $4,585—shows better productivity among the survivors, but it has not offset the shrinking network. This is the key reason the earnings beat does not yet amount to evidence that the Trilivy strategy is working at scale.
The cost reset is producing a cleaner base, but it also exposed how far sales have fallen. Catalyst charges drove the reported operating loss to $19.4 million from $4.1 million a year earlier, while adjusted operating loss improved modestly to $4.0 million. Adjusted EBITDA excluding interest income rose only to $1.9 million from $1.7 million, so the quarter shows cost containment more clearly than a genuine revenue recovery.
Management is still targeting fourth-quarter profitability, but that forecast is now the main proof point for the turnaround. Q4 guidance calls for revenue of $55 million to $75 million, income per share of $0.00 to $0.25, and adjusted EBITDA excluding interest income of $2 million to $6 million. The balance sheet gives Medifast time to execute—with $172.5 million of cash, cash equivalents and investments and no debt—but it does not solve the shrinking coach base.
Bottom line: This is an adjusted earnings beat with a still-deteriorating core network. Medifast is buying time through restructuring and stronger productivity from remaining coaches, but Q4 profitability must arrive while coach attrition continues for the pivot to become credible.
Q4 2026 results and profitability test
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!